Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM‐3

Abstract

SummaryThe physical and emotional burden of relapsed or refractory multiple myeloma (RRMM) has been strongly correlated with declining health‐related quality of life (QOL) in the patients it affects. This analysis evaluated patient‐reported outcomes (PROs) from B‐cell maturation antigen (BCMA)‐naive (n = 123) and ‐exposed (n = 64) patients with RRMM enrolled in the MagnetisMM‐3 study (NCT04649359) and treated with the humanized, bispecific BCMA‐CD3 antibody elranatamab. Patients received two step‐up doses of elranatamab (12 mg on day 1, 32 mg on day 4) before starting the full dose of 76 mg on day 8 (each cycle = 28 days). Global health status, functioning and symptom data were collected electronically using validated and myeloma‐specific questionnaires. Improvements in PROs occurred early, with marked reductions in pain and disease symptoms and notable improvements in patients’ outlook for their future health. Additionally, 40.2% of BCMA‐naive and 52.6% of BCMA‐exposed patients perceived their disease as ‘a little better’ or ‘much better’ by Cycle 1, Day 15. The results from this analysis demonstrated that elranatamab maintained or improved symptomology and general health status, regardless of prior BCMA‐directed therapy. Thus, in addition to its clinical benefits, elranatamab therapy may sustain or improve QOL in heavily pretreated patients with RRMM.